Marksans Pharma Ltd receives USFDA approval for Benzonatate Capsules USP, 100 mg & 200 mg (Rx)

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces the final approval of the Company's Abbreviated New Drug Application (ANDA) for Benzonatate Capsules USP, 100 mg & 200 mg (Rx) from USFDA.

This product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Tessalon Capsules, 100 mg and 200 mg, of Pfizer Inc.

Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract, reducing the cough reflex and relieving persistent cough, bronchitis, pneumonia or other lung infections.

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 168.00 as compared to the previous close of Rs. 157.15. The total number of shares traded during the day was 64399 in over 1511 trades.

The stock hit an intraday high of Rs. 171.25 and intraday low of 160.35. The net turnover during the day was Rs. 10755952.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 Pharmaceuticals ANDA USFDA FinalApproval BenzonatateCapsules